N-Propyltryptamine

N-Propyltryptamine
Clinical data
Other namesNPT; N-n-Propyltryptamine
Drug classSerotonin receptor modulator
ATC code
  • None
Identifiers
  • N-[2-(1H-indol-3-yl)ethyl]propan-1-amine
PubChem CID
ChemSpider
Chemical and physical data
FormulaC13H18N2
Molar mass202.301 g·mol−1
3D model (JSmol)
  • CCCNCCC1=CNC2=CC=CC=C21
  • InChI=1S/C13H18N2/c1-2-8-14-9-7-11-10-15-13-6-4-3-5-12(11)13/h3-6,10,14-15H,2,7-9H2,1H3
  • Key:KBFBIAGUZWNRFI-UHFFFAOYSA-N

N-Propyltryptamine (NPT) is a serotonin receptor modulator of the tryptamine family related to N-methyltryptamine (NMT). According to Alexander Shulgin in his book TiHKAL (Tryptamines I Have Known and Loved), NPT is not known to have been tested in humans. It acts as a serotonin receptor agonist in the rat uterus and stomach strip, with slightly lower potency than dimethyltryptamine (DMT). However, in contrast to DMT and NMT, NPT did not cause central effects in dogs. It is said to be less toxic than dipropyltryptamine (DPT) in rodents. The chemical synthesis of NPT has been described. NPT was first described in the scientific literature by Speeter and Anthony by 1954. Subsequently, the drug was described by Shulgin in TiHKAL in 1997.